Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy

  • S Scabini
  • , M Trunfio
  • , V Pirriatore
  • , D Imperiale
  • , S Audagnotto
  • , R Bertucci
  • , V Ghisetti
  • , G Cinnirella
  • , A Cistaro
  • , M Perna
  • , Andrea CALCAGNO
  • , Perri G. Di

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

A case of progressive multifocal leukoencephalopathy (PML) is described in an HIV-negative patient with mixed connective-tissue disease (MCTD) on a minimally immunosuppressive treatment with hydroxychloroquine. The patient presented with right-sided weakness, episodes of disorientation and loss of short-term memory and of vision in her right eye. PML was diagnosed by JCV DNA on cerebrospinal fluid and radiological criteria. She was treated with off-label maraviroc and mirtazapine but died two months after hospital admission, despite a surprising decrease in the viral load of cerebrospinal fluid three weeks after starting therapy. Prompt diagnosis and antiviral treatment of PML even in low-risk patients are warranted. Future studies are required to define the therapeutic role of maraviroc (MVC) and mirtazapine in this setting.
Lingua originaleInglese
pagine (da-a)160-163
Numero di pagine4
RivistaLE INFEZIONI IN MEDICINA
Volume26
Numero di pubblicazione2
Stato di pubblicazionePubblicato - 2018

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

Fingerprint

Entra nei temi di ricerca di 'Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy'. Insieme formano una fingerprint unica.

Cita questo